Preview

Current Pediatrics

Advanced search

EXPERIENCE OF TREATMENT WITH ABATACEPT IN CHILD WITH JUVENILE RHEUMATOID ARTHRITIS AND SECONDARY INEFFICIENCY OF INFLIXIMAB

Abstract

Opportunities of effective treatment of juvenile arthritis became wide because of introduction of genetically engineered biological drugs to the clinical practice during last years. One of the genetically engineered drugs of first choice for the treatment of refractory types of juvenile arthritis is tumor necrotizing factor blocker infliximab. Nowadays the problem of its primary and secondary inefficiency becomes topical. The article presents an experience of treatment with abatacept in patient with polyarticular type of juvenile rheumatoid arthritis with eyes lesion. Successful treatment with abatacept in patient with high active polyarthritis and uveitis resistant to infliximab proves reasonability of therapy of different clinical symptoms of juvenile arthritis with abatacept.
Key words: children, juvenile rheumatoid arthritis, infliximab, abatacept, treatment.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2011; 10 (3): 170–174)

About the Authors

I.P. Nikishina
Scientific Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow


V.A. Malievskiy
Bashkiriya State Medical University, Ufa


E.S. Fedorov
Scientific Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow


E.P. Pervushina
Republic Children’s Clinical Hospital, Ufa


A.Zh. Nuriakhmetova
Republic Children’s Clinical Hospital, Ufa


References

1. Zulian F., Balzarin M., Falcini F. et al. Abatacept for severe Anti-Tumor Necrosis Factor-refractory juvenile idiopathic arthritis related uveitis. Arthr. Care Res. 2010; 62 (6): 821–825.

2. Angeles-Han S., Flynn T., Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: a case report. J. Rheumatol. 2008: 35: 1897–1898.

3. Saurenmann R.K., Levin A.V., Feldman B.M. et al. Risk of new onset uveitis in patients with juvenile idiopathic arthritis treatment with anti–TNF agent. J. Pediatr. 2006: 149: 833–836.

4. Foeldvari I., Nielsen S., Kummerle–Deschner J. et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis associated uveitis refractory to second-line agents: results of a multinational survey. J. Rheumatol. 2007; 34: 1146–1150.

5. Ruperto N., Lovell D.J., Quartier P. et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008; 372 (9636): 383–391.

6. Ruperto N., Lovell D.J., Li T. et al. Abatacept improves health-related quality of life, pain, sleep quality and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res. 2010; 62 (11): 1542–1551.

7. Ruperto N., Lovell D.J., Quartier P. et al. Longterm safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010; 62 (6): 1792–1802.

8. Ruperto N., Lovell D.J., Cuttica R. et al. Long term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open label treatment extension. Ann Rheum. Dis. 2010; 69 (4): 718–722.


Review

For citations:


Nikishina I., Malievskiy V., Fedorov E., Pervushina E., Nuriakhmetova A. EXPERIENCE OF TREATMENT WITH ABATACEPT IN CHILD WITH JUVENILE RHEUMATOID ARTHRITIS AND SECONDARY INEFFICIENCY OF INFLIXIMAB. Current Pediatrics. 2011;10(3):170–174.

Views: 449


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)